Brief: Fortress Biotech Subsidiary Helocyte Announces Option Agreement With City Of Hope For Exclusive Worldwide Rights To Use A Novel Bispecific CMV/HIV CAR T Cell Therapy
16/10/2023 14:29
Oct 16 (Reuters) - Fortress Biotech Inc FBIO.O :
* FORTRESS BIOTECH SUBSIDIARY HELOCYTE ANNOUNCES OPTION
AGREEMENT
WITH CITY OF HOPE FOR EXCLUSIVE WORLDWIDE RIGHTS TO USE A NOVEL
BISPECIFIC CMV/HIV CAR T CELL THERAPY (OPTIONALLY IN COMBINATION
WITH TRIPLEX) FOR THE TREATMENT OF ADULTS LIVING WITH HIV-1
Source text for Eikon: ID:nGNX8bDr7G
Further company coverage: FBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi